JNJ 28045446

Drug Profile

JNJ 28045446

Alternative Names: JNJ-28045446

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class
  • Mechanism of Action Platelet ADP receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in USA
  • 03 Aug 2007 Preclinical trials in Thrombosis in USA (unspecified route)
  • 03 Aug 2007 Data presented at the 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH-2007) added to the pharmacokinetics and Thromboses pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top